In 2017, the report found all low- and middle-income countries could access entecavir, which is used to treat hepatitis B, and all but two could access the infection treatment tenofovir.
Despite a decrease in the median price of generic tenofovir, from $208 per year of treatment in 2004 to $32 in 2016, treatment rates are still low, the CDC found.
“Taking advantage of reductions in price of antivirals active against [hepatitis B virus] infection could further increase access to treatment,” the agency wrote. “Regular analysis of the hepatitis B treatment care cascade can assist in monitoring progress toward [hepatitis B virus] elimination goals.”
More articles on clinical leadership and infection control:
Health officials praise Kentucky for hep A outbreak response
New hand hygiene data collection process uses Google
44 states affected by salmonella outbreak tied to live poultry
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
